)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cessatech
Cessatech (CESSA) investor relations material
Cessatech Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Advanced paediatric pipeline with new CT004 program in collaboration with Rigshospitalet; Phase II study initiated and global rights retained.
Achieved milestone with first commercial batch of CT001 released in the U.S., enabling launch activities with initial hospitals.
European regulatory process for CT001 ongoing after negative CHMP opinion; re-examination process initiated with EMA.
Maintains focus on capital efficiency and partner-driven commercialisation model.
Financial highlights
Net revenue for Q2 2026 was DKK 0, compared to DKK 1,243,000 in Q2 2025.
Operating result for Q2 2026 was DKK -3,469,000, nearly unchanged from DKK -3,554,000 in Q2 2025.
Net loss for Q2 2026 was DKK -2,773,000, similar to DKK -2,785,000 in Q2 2025.
Cash at bank at period end was DKK 2,348,000, down from DKK 15,051,000 at Q2 2025 end.
Total equity as of 30 June 2026 was DKK 6,393,000.
Outlook and guidance
Company expects minimal clinical and CMC costs for CT001 for the remainder of 2026 as development concludes.
Loan facility of DKK 10,000,000 extended to 2027, supporting U.S. launch and providing financial flexibility.
Cash position does not include the loan facility or expected tax return due in Q4 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cessatech
- CT001 nears commercialization; Q1 loss narrows, cash position remains strong.CESSA
Q1 2026 - CT001 advanced to regulatory review, financials improved, but going concern risk persists.CESSAQ4 2025
- CT001 advanced to EMA review, with Q3 loss and cash boosted by a successful share issue.CESSAQ3 2025
- Strong clinical results and capital raise drive regulatory and commercial progress for CT001.CESSAQ2 2025
- Proveca deal, clinical progress, and improved Q3 results position Cessatech for future growth.CESSAQ3 2024
- Q2 2024 saw no revenue, a DKK -3.4M loss, and key progress toward CT001's US launch.CESSAQ2 2024
- Net loss narrowed and cash strengthened as Cessatech advanced CT001 toward commercialization.CESSAQ4 2024
- Q1 2025 saw Cessatech advance CT001 toward EMA submission, with net loss in line with expectations.CESSAQ1 2025
Next Cessatech earnings date
Q3 202626 Nov, 2026
Cessatech
Next Cessatech earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cessatech is a biopharmaceutical company developing non-invasive treatments for pain management, particularly in pediatric patients. It focuses on innovative anesthetic and analgesic formulations. The company is headquartered in Copenhagen, Denmark, and its shares are listed on the Spotlight Stock Market.